Education
About Us
Working with TipRanks
Follow Us
Lyell Immunopharma, Inc. (LYEL)
:LYEL
LYEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.65 - $32.00
Previous CloseN/A
Volume124.06K
Average Volume (3M)28.51K
Market Cap
$246.29M
Enterprise Value-$99.42M
Total Cash (Recent Filing)$276.79M
Total Debt (Recent Filing)$46.60M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Nov 11, 2025EPS Estimate
-2.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.89
Shares Outstanding19,211,203
10 Day Avg. Volume26,528
30 Day Avg. Volume28,513
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.40
Enterprise Value/Revenue-1.66K
Enterprise Value/Gross Profit-1.66K
Enterprise Value/Ebitda0.50
Forecast
1Y Price Target
$11.00Price Target Upside-14.20% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
EfficacyLYL314 has shown promising early complete responses lasting at least 6 months, equating to ~51% of all treated patients maintaining durable complete responses for six months.
SafetySafety looks encouraging, with no Grade 3+ cytokine release syndrome and 14% Grade 3 immune effector cell-associated neurotoxicity syndrome that resolve relatively quickly.
Bears Say
CompetitionIncreasing competition among CAR-T products for B cell lymphomas as well as personnel changes at the FDA may increase the risk of clinical development.
Lyell Immunopharma News
LYEL FAQ
What was Lyell Immunopharma, Inc.’s price range in the past 12 months?
Lyell Immunopharma, Inc. lowest stock price was $7.65 and its highest was $32.00 in the past 12 months.
What is Lyell Immunopharma, Inc.’s market cap?
Lyell Immunopharma, Inc.’s market cap is $246.29M.
When is Lyell Immunopharma, Inc.’s upcoming earnings report date?
Lyell Immunopharma, Inc.’s upcoming earnings report date is Nov 11, 2025 which is in 57 days.
How were Lyell Immunopharma, Inc.’s earnings last quarter?
Lyell Immunopharma, Inc. released its earnings results on Aug 12, 2025. The company reported -$2.89 earnings per share for the quarter, beating the consensus estimate of -$3.52 by $0.63.
Is Lyell Immunopharma, Inc. overvalued?
According to Wall Street analysts Lyell Immunopharma, Inc.’s price is currently Overvalued.
Does Lyell Immunopharma, Inc. pay dividends?
Lyell Immunopharma, Inc. does not currently pay dividends.
What is Lyell Immunopharma, Inc.’s EPS estimate?
Lyell Immunopharma, Inc.’s EPS estimate is -2.75.
How many shares outstanding does Lyell Immunopharma, Inc. have?
Lyell Immunopharma, Inc. has 19,211,203 shares outstanding.
What happened to Lyell Immunopharma, Inc.’s price movement after its last earnings report?
Lyell Immunopharma, Inc. reported an EPS of -$2.89 in its last earnings report, beating expectations of -$3.52. Following the earnings report the stock price went up 2.46%.
Which hedge fund is a major shareholder of Lyell Immunopharma, Inc.?
Currently, no hedge funds are holding shares in LYEL
Lyell Immunopharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$11.00 (-14.20% Downside)
$11.00 (-14.20% Downside)
Blogger Sentiment
Bullish
LYEL Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 95.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $129.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.26%
12-Months-Change
Fundamentals
Return on Equity
-76.59%
Trailing 12-Months
Asset Growth
-41.08%
Trailing 12-Months
Company Description
Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
LYEL Stock 12 Month Forecast
Average Price Target
$11.00
▼(-14.20% Downside)
Technical Analysis
Ownership Overview
15.94% Insiders
7.07% Mutual Funds
19.78% Other Institutional Investors
50.74% Public Companies and
Individual Investors